Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation
Eli Lilly and Company (NYSE: LLY) announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC). The findings will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on June 4, 2012.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.